ramarketing review: highlights, insights & spotlights - November
ramarketing
We deliver commercial impact globally for companies that target the pharma and biotech sector.
Bringing you insights from stories hitting the headlines across the life sciences sector in the past month.?
The ramarketing review offers vital industry insight to keep you in the know, featuring a different ramarketing expert each month to deliver headline highlights. If you’d like to receive updates straight to your inbox, sign up here.
Introducing the November sector expert…
Caitlin joined ramarketing as a Senior Scientific Content Specialist and uses her scientific background to deliver technically accurate and engaging content that aligns with the strategic goals of our biopharma and pharmaceutical clients.
Working within the medical device and biopharmaceutical companies as a researcher in downstream processing departments, Dr Richardson applied her in-depth scientific knowledge and analytical skills to optimise protein purification. As a result, she has a comprehensive understanding of the requirements and processes involved in developing diagnostic kits, drug substances, and drug products.
Biologics revenue to overtake small molecules in solid tumor treatment by 2027
The pharmaceutical landscape has long been dominated by small molecules, which accounted for 75% of all approved pharmaceuticals in 20201. Setting the scene for a new era, biologics are now poised to overtake small molecules in terms of sales revenue by 2027, with forecast sales of $120 billion.?
Biologics have already become the leading molecule type within the solid tumor indication — accounting for 64% of drugs — with many new cancer-targeting therapeutics currently in development.?
Recognizing the potential of biologics in the treatment of various cancer types, biotechs are heavily investing in the development of these medicines.?
Just this month, Novartis announced it was deepening its investment in cancer cell therapy, licensing an experimental antibody-drug conjugate (ADC) project developed by Legend Biotech for two types of lung cancer, currently in early-stage trials.
Bristol Myers Squibb is also in the process of acquiring an ADC to treat bone and blood cancers from multinational biotechnology startup Orum Therapeutics.
Jefferies Healthcare Conference: How CDMOs are embracing obesity drugs craze
Global obesity has nearly tripled since 1975; now more than 1 billion people worldwide are obese and this number is still increasing. WHO estimates that by 2025, approximately 167 million people will become less healthy because they are overweight or obese4.
As a complex disease impacting most body systems, including the heart, liver, kidneys, joints and the reproductive system, obesity is not only impacting global health but, crucially, healthcare systems. In fact, obesity is estimated to account for more than 20% of all annual healthcare expenditures in the United States5.
领英推荐
Sales of branded anti-obesity drugs have been a key topic of conversation this past month, being anticipated to reach $44 billion in 2023. Glucagon-like peptide 1 (GLP-1) agonists helping people lose weight through several mechanisms — including slowing down stomach emptying and reducing appetite by acting on the brain — have been the subject of particularly ambitious sales forecasts6.
The biotech industry is reacting quickly to this increased demand for GLP-1 and other obesity medications, with companies like Novo Nordisk and Eli Lilly taking steps to expand the production of their obesity drugs, Mounjaro and Wegovy, respectively.?
The contract development and manufacturing organization (CDMO) sector can expect to see the impact of the growing obesity drug market, with the need to demonstrate that it can scale production to meet future demand.?
UK launches vaccine development hubs in $43 million project
Reflecting on the critical role vaccines played throughout the COVID-19 pandemic, the UK launched four hubs dedicated to the development of vaccines for diseases with epidemic potential in low- and middle-income countries, with ￡34.5 million ($42.8 million) in funding.
The hubs will address reports of slow vaccination progress in some countries, with many people having insufficient access to vaccines — including nearly 20 million infants per year2.
The hubs will bring together researchers from around the globe and specialize in different aspects of supplying vaccines to the developing world. The Future Vaccine Manufacturing Research Hub will aim to provide flexible, low-cost and scalable vaccine manufacturing and deployment in Vietnam, Bangladesh and South Africa3.
Stay tuned for more ramarketing review installments — who will be next month’s guest expert? You’ll have to be subscribed to our mailing list to find out…
References